NIH opening funding for mobile health projects

Two National Institutes of Health organizations plan to award funding for mobile health tools that help with the treatment and self-management of chronic diseases among underserved populations.

The National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) are looking for applications from multiple entities, including higher education institutions; not-for-profit groups; for-profit groups; and government agencies.

NINR is interested in mobile health tools and research that can aid patients with chronic diseases, including tools to help underserved populations; improve patient-provider communication; help patients effectively manage their diseases; and improve patients' adherence to treatments.

Meanwhile, NIBIB is interested in the research and development of new imaging and bioengineering technologies.

Interested groups can begin submitting their applications on May 5 for projects of a maximum length of five years.

The number of awards that the NIH organizations give out will depend on appropriations and the number of worthy applications.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.